Grifols Shared Services North America has purchased 100% stake in Biotest US Corporation and its operating subsidiary, Biotest Pharmaceuticals Corporation (BPC), for $286m.

BPC is a US-based manufacturer of bio-therapeutic products specialising in the development of plasma protein products. The plasma collected at Biotest Plasma Centers is utilised to produce therapies for life-threatening diseases in various therapeutic areas.

The acquisition, which was funded through Grifols’ own resources, includes 22 plasma collection centres, two under-construction centres, and other corporate offices of BPC located in Florida.

Based in the US, Grifols is a healthcare company focused on the production of plasma-derived biopharmaceutical products.

The acquisition is part of Grifols’ strategy to expand its network of donation centres that was initiated in 2015 and to increase the production of raw materials used in the plasma-derived therapies. It will also enable the company to expand its plasma collection network to 249 centres across the US.

“Takeda Pharmaceuticals has acquired 100% stake in TiGenix for $608.84m.”

Takeda Pharmaceuticals has acquired 100% stake in TiGenix for $608.84m.

The transaction, first announced in January this year, was closed following the expiry of squeeze-out period, which commenced on 6 July and ended on 26 July.

TiGenix will operate as a wholly owned subsidiary of Takeda, following the acquisition.

Based in Japan, Takeda is a pharmaceutical company that provides medicines for unmet medical needs such as inflammatory bowel disease and motility disorders, while TiGenix is a biopharmaceutical company engaged in the development and commercialisation of innovative therapeutics for autoimmune and inflammatory diseases.

The transaction enables the acquirer company to boost its late-stage gastroenterology pipeline and expand its footprint in the specialist care market in the US.

It will also expand an existing collaboration signed between Takeda and TiGenix in July 2016 towards the development and commercialisation of the latter’s investigational compound, Cx601, in markets excluding the US.